Cross-Titration from Brexpiprazole (Rexulti) 0.5 mg to Quetiapine (Seroquel) 25 mg
There is no established evidence-based protocol for cross-titrating from brexpiprazole to quetiapine at these specific low doses, so a conservative approach prioritizing safety is warranted.
Recommended Cross-Titration Strategy
Week 1: Initiate Quetiapine
- Start quetiapine 25 mg at bedtime while continuing brexpiprazole 0.5 mg daily 1, 2
- Quetiapine 25 mg is an appropriate starting dose for older or frail patients and those requiring lower doses 1, 2
- Monitor for additive sedation, orthostatic hypotension, and dizziness during this overlap period 1
Week 2: Reduce Brexpiprazole
- Decrease brexpiprazole to 0.25 mg daily (half the dose) while maintaining quetiapine 25 mg at bedtime
- Brexpiprazole has a long half-life (approximately 91 hours), so gradual tapering minimizes withdrawal effects 3, 4
- Continue monitoring for psychiatric symptom changes and side effects
Week 3: Discontinue Brexpiprazole
- Stop brexpiprazole completely while continuing quetiapine 25 mg at bedtime
- The gradual taper over 2 weeks allows for steady-state clearance of brexpiprazole 3, 4
Week 4 and Beyond: Assess Response
- Maintain quetiapine 25 mg at bedtime and evaluate clinical response over 2-4 weeks 2
- If inadequate symptom control, quetiapine can be titrated upward in 25-50 mg increments every 2-3 days as tolerated 2
- The maximum dose depends on indication but typically ranges from 150-800 mg/day for psychiatric conditions 2
Critical Monitoring Parameters
During the cross-titration period, monitor for:
- Orthostatic hypotension and falls risk - both medications can cause postural hypotension, with additive effects during overlap 1
- Excessive sedation - quetiapine is notably sedating, particularly at bedtime dosing 1
- Psychiatric symptom exacerbation - watch for emergence or worsening of psychosis, agitation, or mood symptoms 1, 5
- Extrapyramidal symptoms (EPS) - though less likely at these low doses, monitor for akathisia or parkinsonism 1
- Metabolic effects - both agents can cause weight gain and metabolic changes with longer-term use 1, 2
Important Clinical Caveats
Rationale for gradual cross-titration: While abrupt switching between antipsychotics can be done in some cases 5, the conservative approach outlined above minimizes risk of symptom relapse and withdrawal effects, particularly given the very low doses involved 1, 6.
Bedtime dosing consideration: Quetiapine 25 mg at bedtime is appropriate for minimizing daytime sedation while providing therapeutic benefit 1, 7. If twice-daily dosing becomes necessary with dose escalation, split the total daily dose 2.
Special populations: If the patient is elderly, has hepatic impairment, or takes CYP3A4 inhibitors, even slower titration and lower doses may be warranted 2.
Duration of adequate trial: Allow at least 4-6 weeks at the target quetiapine dose before determining efficacy, as antipsychotic response can take time to manifest 1, 5.